Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.51 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 2/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | CDC7 | O00311 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | PRKACA | P17612 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1584889 | 0.85 | PIM1 (0.56) | PIM1PIM3CHEK1FLT3AKT1 | |
| SCHEMBL13003705 | 0.79 | PARP1 (0.54) | PIM1CHEK1IDO1RPS6KA3MEN1 | |
| SCHEMBL29638516 | 0.79 | PARP1 (0.54) | PIM1CHEK1IDO1RPS6KA3MEN1 | |
| SCHEMBL1345856 | 0.79 | PARP1 (0.50) | CHEK1IDO1 | |
| SCHEMBL2191216 | 0.79 | ALDH1A1 (0.55) | PIM1PIM3CDC7CSNK2A1PIM2 | |
| SCHEMBL1663769 | 0.79 | PRKCI (0.56) | PIM1PIM3CHEK1FLT3AKT1 | |
| SCHEMBL29798728 | 0.79 | PARP1 (0.50) | CHEK1IDO1 | |
| SCHEMBL1663176 | 0.79 | LMNA (0.51) | ADRA1AADRA1BPDPK1CDK5CDK5R1 | |
| SCHEMBL144025 | 0.79 | PARP1 (0.50) | PIM1PIM3CHEK1FLT3AKT1 | |
| SCHEMBL8870966 | 0.75 | CSNK2A1 (0.49) | CSNK2A2CSNK2BCSNK2A1DYRK1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2022-12-13 | — | — | US | disclosed |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | KANION USA INC. | 2021-02-18 | — | — | US | disclosed |
| EP-2680850-B1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS INC (US) | 2016-02-04 | — | — | US | disclosed |
| US-9090588-B2 | Alkyne substituted quinazoline compound and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2680850-A2 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | Newgen Therapeutics, Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012122058-A2 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128417-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | PIM1 236/4885PIM3 280/4885CHEK1 87/4885 |
| US-20160031860-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | PIM1 236/4885PIM3 280/4885CHEK1 87/4885 |
| US-11524956-B2 | Alkyne substituted quinazoline compound and methods of use | ERBB2, ERBB4, ERBB3 | PIM1 236/4885PIM3 280/4885CHEK1 87/4885 |
| US-20180093975-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | PIM1 236/4885PIM3 280/4885CHEK1 87/4885 |
| US-20210047303-A1 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | ERBB2, ERBB4, ERBB3 | PIM1 236/4885PIM3 280/4885CHEK1 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.